CTSH vs DOCS
Cognizant Technology Solutions Corp. and Doximity, Inc., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CTSH | DOCS |
|---|---|---|
| Revenue | $21.1B | $644.9M |
| Net income | $2.2B | $196.1M |
| Gross margin | 33.7% | 89.1% |
| Net margin | 10.6% | 30.4% |
| Return on equity | 15.2% | 19.3% |
| Diluted EPS | $4.56 | $0.98 |
| Dividend / share | $1.24 | · |
| Payout ratio | 27.4% | · |
| Free cash flow | $2.6B | $326.5M |
| Equity | $15.0B | $950.8M |
| Net debt / equity | −0.09× | · |
| Current ratio | 2.14× | 6.09× |
| Revenue CAGR 5y | 4.9% | 25.5% |
| Profit CAGR 5y | 9.9% | 31.3% |
CTSH bills 32.7× the revenue of DOCS, and DOCS keeps more of each dollar of revenue as profit (30.4% against 10.6%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | CTSH | DOCS |
|---|---|---|
| FY2025 | $21.1B | $644.9M |
| FY2024 | $19.7B | $570.4M |
| FY2023 | $19.4B | $475.4M |
| FY2022 | $19.4B | $419.1M |
| FY2021 | $18.5B | $343.5M |
| FY2020 | $16.7B | $206.9M |
| FY2019 | $16.8B | $116.4M |
Bottom line
| Fiscal year | CTSH | DOCS |
|---|---|---|
| FY2025 | $2.2B | $196.1M |
| FY2024 | $2.2B | $223.2M |
| FY2023 | $2.1B | $147.6M |
| FY2022 | $2.3B | $112.8M |
| FY2021 | $2.1B | $154.8M |
| FY2020 | $1.4B | $50.2M |
| FY2019 | $1.8B | $29.7M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$20,463,137,000 | CTSH |
| FY2024 | +$19,165,601,000 | CTSH |
| FY2023 | +$18,877,578,000 | CTSH |
| FY2022 | +$19,008,948,000 | CTSH |
| FY2021 | +$18,163,452,000 | CTSH |
| FY2020 | +$16,445,103,000 | CTSH |
| FY2019 | +$16,666,612,000 | CTSH |
CTSH has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −19.8 pp | DOCS |
| FY2024 | −27.8 pp | DOCS |
| FY2023 | −20.1 pp | DOCS |
| FY2022 | −15.1 pp | DOCS |
| FY2021 | −33.5 pp | DOCS |
| FY2020 | −15.9 pp | DOCS |
| FY2019 | −14.6 pp | DOCS |
DOCS has kept the higher net margin in every one of these 7 fiscal years.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
DOCS's net margin has been more volatile than CTSH's over the 7 comparable fiscal years — 7.1 percentage points of standard deviation against 1.1.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
DOCS led in net margin in every one of the 7 comparable fiscal years — a structural lead, not a recent swing.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
DOCS's return on equity has been more volatile than CTSH's over the 7 comparable fiscal years — 902.5 percentage points of standard deviation against 1.9.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CTSH and DOCS over these 7 fiscal years — CTSH led in 2 and DOCS in 5.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.